Heart rate variability (HRV) is a noninvasive technique for autonomic nerve activity assessment and
an indirect index of adrenergic cardiovascular drive. Renalase is the only known enzyme degrading circulatory
catecholamines, participating in regulations of the cardiovascular and sympathetic nervous systems. This study
aims at the relation between serum renalase and HRV indexes in dialysis patients. There were 14 hemodialysis (HD)
cases, 16 continuous ambulatory peritoneal dialysis (PD) cases, and 16 healthy volunteers enrolled in this study.
All the subjects underwent 24 h Holter testing by using a dynamic electocardiogram monitor system to determine
HRV parameters, and serum renalase levels were measured. The standard deviation of normal to normal R-R
intervals (SDNN, a measure of beat-to-beat variability), root mean square successive difference (RMSSD), and the
proportion derived by dividing NN50 (the number of interval differences of successive normal to normal intervals
greater than 50ms) by the total number of NN intervals (pNN50) were determined to assess HRV. Both HD and
PD patients presented increased maximum heart rate (Max-HR), minimum heart rate (Min-HR) and average
heart rate (Ave-HR), and presented decreased SDNN, RMSSD and pNN50 relative to healthy controls. Serum
levels of renalase were highly negatively correlated with Ave-HR (correlation coefficient r = ?0.68, probability
P < 0.01), while positively correlated with SDNN (r = 0.64, P < 0.01) in both the HD and PD groups. Serum
level of renalase was positively correlated with 24 h urine volume (r = 0.73, P < 0.01) in PD patients. Renalase
might be reciprocally related to HRV and inversely related to Ave-HR in dialysis patients, which will help to
probe into renalase’s physiology and may pave the way to explore renalase replacement therapy in patients with
end stage renal disease (ESRD).
[1] Lahiri M K, Kannankeril P J, Goldberger J J. Assessment of autonomic function in cardiovascular disease: Physiological basis and prognostic implications [J]. Journal of the American College of Cardiology,2008, 51(18): 1725-1733.
[2] Malpas S C. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease [J]. Physiological Reviews, 2010, 90(2): 513-557.
[3] Rump L C, Amann K, Orth S, et al. Sympathetic overactivity in renal disease: A window to understand progression and cardiovascular complications of uraemia? [J]. Nephrology Dialysis Transplantation,2000, 15(11): 1735-1738.
[4] Amann K, Rump L C, Simonaviciene A, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats [J]. Journal of the American Society of Nephrology, 2000, 11(8): 1469-1478.
[5] Converse R L, Jr Jacobsen T N, Toto R D, et al.Sympathetic overactivity in patients with chronic renal failure [J]. New England Journal of Medicine, 1992,327(27): 1912-1918.
[6] Go A S, Chertow G M, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [J]. New England Journal of Medicine, 2004, 351(13): 1296-1305.
[7] Rubinger D, Backenroth R, Sapoznikov D. Sympathetic nervous system function and dysfunction in chronic hemodialysis patients [J]. Seminars in Dialysis,2013, 26(3): 333-343.
[8] Shroff R, Degi A, Kerti A, et al. Cardiovascular risk assessment in children with chronic kidney disease [J]. Pediatric Nephrology, 2013, 28(6): 875-884.
[9] Robinson T G, Carr S J. Cardiovascular autonomic dysfunction in uremia [J]. Kidney International, 2002,62(6): 1921-1932.
[10] Parati G, Saul J P, Di Rienzo M, et al. Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation: A critical appraisal[J]. Hypertension, 1995, 25(6): 1276-1286.
[11] Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure [J]. Hypertension, 2011,57(4): 846-851.
[12] Chan C T, Chertow G M, Daugirdas J T, et al. Effects of daily hemodialysis on heart rate variability:Results from the frequent hemodialysis network (FHN) daily trial [J]. Nephrology Dialysis Transplantation,2014, 29(1): 168-178.
[13] Nishimura M, Tokoro T, Nishida M, et al. Sympathetic overactivity and sudden cardiac death among hemodialysis patients with left ventricular hypertrophy[J]. International Journal of Cardiology, 2010,142(1): 80-86.
[14] Desir G V. Regulation of blood pressure and cardiovascular function by renalase [J]. Kidney International,2009, 76(4): 366-370.
[15] Desir G V. Role of renalase in the regulation of blood pressure and the renal dopamine system [J]. Current Opinion in Nephrology and Hypertension, 2011, 20(1):31-36.
[16] Wang F, Huang B, Li J, et al. Renalase might be associated with hypertension and insulin resistance in type 2 diabetes [J]. Renal Failure, 2014, 36(4): 552-556.
[17] Wang F, Li J, Xing T, et al. Serum renalase is related to catecholamine levels and renal function [J]. Clinical Experimental Nephrology, 2014. DOI 10.1007/s10157-014-0951-8 (published online).
[18] Schlaich M P, Socratous F, Hennebry S, et al.Sympathetic activation in chronic renal failure [J].Journal of the American Society of Nephrology, 2009,20(5): 933-939.
[19] Wang F, Xing T, Li J, et al. Renalase’s expression and distribution in renal tissue and cells [J]. PLoS One,2012, 7(10): e46442.
[20] Zhou Y, Wang F, Hao L, et al. Effects of magnoline on P-selectin’s expression in diabetic rats and its reno-protection [J]. Kidney & Blood Pressure Research,2013, 37(2-3): 211-220.
[21] Ranpuria R, Hall M, Chan C T, et al. Heart rate variability (HRV) in kidney failure: Measurement and consequences of reduced HRV [J]. Nephrology Dialysis Transplantation, 2008, 23(2): 444-449.
[22] Rubinger D, Revis N, Pollak A, et al. Predictors of haemodynamic instability and heart rate variability during haemodialysis [J]. Nephrology Dialysis Transplantation,2004, 19(8): 2053-2060.
[23] Rubinger D, Sapoznikov D, Pollak A, et al. Heart rate variability during chronic hemodialysis and after renal transplantation: Studies in patients without and with systemic amyloidosis [J]. Journal of the American Society of Nephrology, 1999, 10(9): 1972-1981.
[24] Sipahioglu M H, Kocyigit I, Unal A, et al. Effect of serum electrolyte and bicarbonate concentration changes during hemodialysis sessions on heart rate variability [J]. Journal of Nephrology, 2012, 25(6):1067-1074.
[25] Tang W, Li L X, Pei J, et al. Heart rate variability in peritoneal dialysis patients: What is the role of residual renal function? [J]. Blood Purification, 2012,34(1): 58-66.
[26] La Rovere M T, Pinna G D, Hohnloser S H, et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: Implications for clinical trials [J]. Circulation,2001, 103(16): 2072-2077.
[27] Oikawa K, Ishihara R, Maeda T, et al. Prognostic value of heart rate variability in patients with renal failure on hemodialysis [J]. International Journal of Cardiology, 2009, 131(3): 370-377.
[28] Wang F, Wang N, Xing T, et al. The cloning and expression of renalase and the preparation of its monoclonal antibody [J]. Journal of Shanghai Jiaotong University (Science), 2009, 14(3): 376-379.
[29] Wang F, Wang N, Xing T. Construction of eukaryotic recombinant vector of renalase and its expression as a eukaryotic protein [J]. Journal of Shanghai Jiaotong University (Science), 2010, 15(5): 637-640.
[30] Desir G V, Tang L, Wang P, et al. Renalase lowers ambulatory blood pressure by metabolizing circulating adrenaline [J]. Journal of the American Heart Association,2012, 1(4): e002634. 1-11.
